These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290 [TBL] [Abstract][Full Text] [Related]
5. Lowering the boom on lower-risk myelodysplastic syndromes. Sekeres MA; Patel BJ Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873 [TBL] [Abstract][Full Text] [Related]
6. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia. Kang C; Syed YY Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460 [TBL] [Abstract][Full Text] [Related]
7. Luspatercept in Myelodysplastic Syndromes: Who and When? Komrokji RS Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218 [TBL] [Abstract][Full Text] [Related]
8. How we manage adults with myelodysplastic syndrome. Fenaux P; Platzbecker U; Ades L Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568 [TBL] [Abstract][Full Text] [Related]
9. Therapy for lower-risk MDS. Carraway HE; Saygin C Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714 [TBL] [Abstract][Full Text] [Related]
10. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066 [No Abstract] [Full Text] [Related]
11. Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports. Shao Y; He L; Ding S; Fu R Curr Res Transl Med; 2024 Mar; 72(1):103438. PubMed ID: 38244303 [TBL] [Abstract][Full Text] [Related]
14. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies. Molica M; Rossi M Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469 [TBL] [Abstract][Full Text] [Related]
15. Luspatercept: First Approval. Markham A Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073 [TBL] [Abstract][Full Text] [Related]
16. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. Mies A; Hermine O; Platzbecker U Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736 [TBL] [Abstract][Full Text] [Related]
17. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A; N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518 [TBL] [Abstract][Full Text] [Related]
18. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat. Tefferi A Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878 [No Abstract] [Full Text] [Related]
19. Treatment of Acquired Sideroblastic Anemias. Mangaonkar AA; Patnaik MM Hematol Oncol Clin North Am; 2020 Apr; 34(2):401-420. PubMed ID: 32089219 [TBL] [Abstract][Full Text] [Related]
20. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts. Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]